| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure
Ashley – Huntington’s Disease Community Advocate Phase I/II ifezuntirgene inilparvovec (AMT-130) Huntington’s Disease Program Update September 29, 2026 |
| 02 Sep 2026 |
8-K: Regulation FD Disclosure
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ |
| 24 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representative (the “Representative”) of the several Underwriters |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy |
| 17 Jun 2026 |
8-K: Other Events
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ |
| 15 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
This is a translation into English of the official Dutch version of the articles of association of a public company with limited liability under Dutch law. Definitions included in article 1 below appear in the English alphabetical order ... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ |
| 30 Apr 2026 |
8-K: Regulation FD Disclosure
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ |
| 13 Jan 2026 |
8-K: Regulation FD Disclosure
Sophia – Huntington’s Disease Community Advocate Leadership in Gene Therapy January 2026 Exhibit 99.1 |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
Lexington, MA and Amsterdam, the Netherlands, January 9, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with ... |
| 04 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Lexington, MA and Amsterdam, the Netherlands, December 4, 2025 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company rece... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary andkey secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 monthsand supportive trend... |
| 03 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Lexington, MA and Amsterdam, the Netherlands, November 3, 2025 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feed... |
| 29 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representative (the “Representative”) of the several Underwriters |
| 24 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
[***] CERTAIN INFORMATION HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10)(IV) FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL |
| 24 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease |
Loading...